Grant: CIHR-ICRH/CAAIF/AZ Canada/AllerGen Emerging Researcher Awards in Allergic Asthma
McMaster University
$200,000.00
Investigating autoimmune responses for tailoring biologic therapies in severe asthma
EF 2019-20
Résumé
Asthma can be very sever for approximately 10% of patients who suffer from significant symptoms, frequent hospitalizations, loss of productivity/income, and impose a significant economic burden. Severity is driven by a type of white blood cells (eosinophils) that gets recurited to the lungs as a result of allergy and other triggers and plugs the airways. This is treated with glucocorticosteroids (prednisone) which causes serious side effects. Antiobodies (biologicals) have been developed that blocks the specific proteins which mediates allergy and further recruits these eosinphils to the lungs. However, for a number of reasons, they are not equally effective for all patients. Our research shows that antibodies in the airways of some patients may interfere with the action of the biologicals. This project will investigate how antibodies might mediate these effects and develop strategies to identify patients in whom these biologicals may not work.
Programme
CIHR-ICRH/CAAIF/AZ Canada/AllerGen Emerging Researcher Awards in Allergic Asthma
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
413281
Name
Mukherjee Manali
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Partnername
Allergen NCE; AstraZeneca Canada Inc.; Canadian Allergy, Asthma and Immunology Foundation
Prcname2
Special Cases
Projecttitle
Investigating autoimmune responses for tailoring biologic therapies in severe asthma
Programtype2
Salary Programs
Orgnameinp2
McMaster University
Cihramount2
$200,000
Cihrequipment2
$0
Programname2
CIHR-ICRH/CAAIF/AZ Canada/AllerGen Emerging Researcher Awards in Allergic Asthma
Keyworddelim
Anri-Il-5; Anti-Lge; Asthma; Autoimmune; Biologics
Abstract
Asthma can be very sever for approximately 10% of patients who suffer from significant symptoms, frequent hospitalizations, loss of productivity/income, and impose a significant economic burden. Severity is driven by a type of white blood cells (eosinophils) that gets recurited to the lungs as a result of allergy and other triggers and plugs the airways. This is treated with glucocorticosteroids (prednisone) which causes serious side effects. Antiobodies (biologicals) have been developed that blocks the specific proteins which mediates allergy and further recruits these eosinphils to the lungs. However, for a number of reasons, they are not equally effective for all patients. Our research shows that antibodies in the airways of some patients may interfere with the action of the biologicals. This project will investigate how antibodies might mediate these effects and develop strategies to identify patients in whom these biologicals may not work.
Competitiondate
201908
Approvedterm2
2 yrs 0 mth
Pinamesdelim
Mukherjee, Manali
Approvedterm
2 ans 0 mois
Cihrcontribution2
Inst of Circ &Respiratory Hlth~ $200,000~ $0~